Formulary Watch |

The broader indication for Zynrelef now covers around 7 million procedures annually and reduces the need for post-surgery opioids.

Consumers have a false sense of security about buying drugs from online platforms.

Blood cancer patients who had at least some antibodies after the first two doses are likely to produce large amounts after the third vaccination.

Researchers suggest that adjusting the prescribing patterns of about 8% of physicians could result in substantial savings.

Medexus is working with Ethypharm to generate the data needed to support an abbreviated new drug application for triamcinolone hexacetonide.

The regulatory agency is reviewing Reata’s application of bardoxolone to treat patients with chronic kidney disease caused by Alport syndrome, a rare genetic disease.

The FDA in late November authorized the COVID-19 booster for all people 18 years of age and older.

Evusheld is the only monoclonal antibody authorized in the United States for COVID-19 pre-exposure prophylaxis.

Pfizer and BioNTech expect to have an omicron-specific booster ready by March 2022.

Preclinical studies show sotrovimab is active against key mutations of the omicron variant of SARS-CoV-2, which causes COVID-19.

The new boxed warning for Xeljanz, Olumiant, and Rinvoq includes the risk of cardiovascular adverse events and cancer.

The approval marks the ninth indication for Darzalex Faspro, the only subcutaneous anti-CD38 monoclonal antibody approved to treat multiple myeloma across multiple treatment regimens.

The warnings section of Inrebic, a JAK inhibitor to treat a bone marrow cancer, now includes information about the cardiovascular risk associated with Xeljanz, another JAK inhibitor to treat arthritis.

CMS is not requiring payment for pharmacists’ testing, patient assessment, ordering/prescribing and dispensing for oral COVID-19 antiviral drugs.

ICER’s first scorecard of the barriers to fair access to medications found that more transparency is needed to fully assess insurers and their coverage policies.

Findings show substantial variation in payer-negotiated prices and self-pay cash prices at top-performing U.S. hospitals and considerable markups on clinician-administered drugs.

The regulatory agency has set a Prescription Drug User Fee Act date during the first quarter of 2022